Journal of Inflammation Research

Targeting the IL-4/IL-13 Axis in the Treatment of Type 2 Inflammation

The Journal of Inflammation Research is pleased to announce a new Article Collection dedicated to the role that drugs targeting the IL-4/IL-13 axis play in the treatment of type 2 inflammatory conditions.

This Collection, edited by the Editor-In-Chief Prof. Ning Quan, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, and technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.

Type 2 inflammation occurs when immune cells, including eosinophils and mast cells, are activated, producing the cytokine IL-4 and Il-13. These cytokines are responsible for signaling the production of eosinophils, mast cells, and IgE antibodies, that lead to the release of more pro-inflammatory cytokines. Type 2 inflammatory conditions affect 10-30% of the global population, and include common conditions such as allergy, asthma, eczema, and eosinophilic esophagitis. By targeting IL-4 and IL-13, overactive immune systems can be regulated, and many patients will see a better quality of life.

While this call is open to receive manuscripts highlighting all aspects of drugs targeting the IL-4/Il-13 axis, the Editors are particularly interested in manuscripts relating to the following areas:

• Clinical studies on the efficacy and safety of IL-4 and/or IL-13 inhibitors
• Novel drug mechanistic actions
• Biologics directed against cells or pathways involved in the IL-4/IL-13 axis
• New drug candidates directed against IL-4 and/or IL-13
• Tailoring treatment in individuals with multiple Type 2 inflammatory conditions
• Drugs to treat non-allergic type 2 inflammation, such as nasal polyps
• Treatment strategies and potential side effects

Submitting authors are eligible for a 20% discount on the Article Publishing charge by applying the following code at the point of submission: YXVCF. If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor Ashley Ambros.

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript as it will be rejected if it does not fall within the scope of the journal.

The deadline for submitting manuscripts is 1^st of April 2026.